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Abstract
Background: Identification of patients at risk of developing adverse events would enable aggressive medical therapy
and possibly targeted revascularization. The aim of this study is to characterize the determinants of long-term
outcomes in atherosclerotic renovascular disease (ARVD).
Methods: Patients with a radiological diagnosis of ARVD were recruited into this single-center prospective cohort study
between 1986 and 2014. Data collected included baseline co-morbid conditions, annualized prescribed medications and
laboratory data (serum creatinine [υmol/L], proteinuria [g/24 h]). Multivariable Cox regression analysis was used to explore
association with these end-points: death, end-stage kidney disease (ESKD), cardiovascular event (CVE) and the first of any
of these events.
Results: A total of 872 patients were recruited into this study. However, 42 patients were excluded due to missing
baseline data and hence case records for 830 patients were reviewed. Over median follow-up of 57.1 months
(interquartile range: 21.7–96.9), incidence per 100 patient years of death, ESKD, CVE and any event was 13.5, 4.2, 8.9 and
21.0 respectively. Macrovascular disease (MVD), congestive heart failure (CHF), flash pulmonary oedema (FPE) and greater
proteinuria at baseline were individually associated with increased risk for all end-points in multivariable analysis (Death:
MVD –HR 1.24 [95% CI 1.02–1.50]; CHF –HR 1.33 [95% CI 1.08–1.64]; FPE – HR 2.10 [95% CI 1.50–2.92]; proteinuria – HR 1.
14 [95% CI 1.08–1.20]). Higher estimated glomerular filtration rate at time of diagnosis was significantly associated with
reduced risk of all end-points (Death: HR 0.92 [95% CI 0.89–0.94])., Administration of statins and renin angiotensin
blockade (RAB) at baseline were also associated with reduced adverse events, especially death (RAB: HR 0.83 [95% CI 0.
70–0.98]; statins: HR 0.79 [95% CI 0.66–.94]) and ESKD (RAB: HR 0.84 [95% CI 0.71–1.00]; statins: HR 0.79 [95% CI 0.66–0.
93]). Revascularization was associated with reduced risk of death (HR 0.65 [95% CI 0.51–0.83]) and ESKD (HR 0.59 [95% CI
0.46–0.76]).
Conclusion: All patients with ARVD require intensive vascular protection therapy to help mitigate systemic
atherosclerosis, optimize cardiovascular risk and improve clinical outcomes. More effort is required to identify the
minority of patients who may benefit from revascularization.
Keywords: Atherosclerotic renovascular disease, Cardiovascular events, End-stage kidney disease, Mortality, Proteinuria,
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Background
With an increasingly aging population and a rising burden
of atherosclerotic risk factors [1], there is a suggestion that
atherosclerotic renovascular disease (ARVD) is becoming
more prevalent both in the general population and in pa-
tients with chronic kidney disease (CKD) [2]. This has im-
portant implications because although ARVD is clinically
silent in the majority of patients, its presence is independ-
ently associated with increased mortality when compared
to patients with similar risk factors but no significant renal
artery stenosis (hazard ratio 2.9 [risk ratio 1.7–7.0] p <
0.0001) [3] or non-ARVD CKD (hazard ratio 1.5 [95%
confidence interval 1.2–1.8] p < 0.0001) [4]. Only a minor-
ity of patients with haemodynamically–significant ARVD
present with a ‘high-risk’ clinical phenotype characterized
by one or more of uncontrolled hypertension, rapid
decline in renal function, and recurrent heart failure [5].
Management of ARVD has been a contentious subject
for many years; recent large randomized controlled trials
(RCT) have shown that revascularization does not confer
added benefit to optimal medical treatment and athero-
sclerotic risk factor control, the accepted cornerstones of
ARVD management [6, 7]. However, as with any RCT,
these findings only apply to the type of patients included in
the trials; those ARVD patients with high-risk features
were seldom recruited into these studies. Anectodal evi-
dence from case reports [8, 9] and more recently, data
from an observational single-center study performed by
our research group comparing medical treatment with re-
vascularization in 237 patients with a high-risk phenotype,
support the role of revascularization in specific clinical sit-
uations. In this study we found that revascularization
reduced the risk of death in patients presenting with
flash pulmonary oedema (hazard ratio 0.4, p = 0.01) and
was associated with reduced risk of death (hazard ratio
0.15, p = 0.04) and cardiovascular events (hazard ratio
0.23, p = 0.02) in patients with the combination of refrac-
tory hypertension and rapidly declining renal function [10].
Accurate identification of patients with ARVD who are
at risk of suffering adverse events would allow a patient-
specific therapeutic approach with targeted, intense med-
ical therapy and the possibility of timely revascularization.
In this study we utilized clinical and laboratory data
acquired over almost 3 decades to characterize the pheno-
type of patients who reached important clinical end-
points, to determine the impact of risk factors on
long-term outcomes and assess the effect of revascu-
larization in a large unselected population of patients
with ARVD.
Methods
Patient population and data collection
All patients with ARVD presenting to our regional
renal centre since 1986 have been recruited into this
observational epidemiological study. Data were collected
on an annual basis from hospital records, in line with eth-
ical approval granted by the local ethics committee and
the declaration of Helsinki. Data collection includes base-
line demographics (age at diagnosis, gender), co-morbid
conditions (diabetes, macrovascular disease [MVD], con-
gestive heart failure [CHF]), presence of flash pulmonary
oedema (FPE), and annualized prescribed medications,
blood pressure, and laboratory data including serum cre-
atinine (υmol/L) and proteinuria (g/24 h), together with
clinical outcome data. The degree of renal artery stenosis
(RAS) was obtained from cross-sectional angiography
(intravenous digital subtraction angiography [IVDSA] and
intra-arterial digital subtraction angiography [IADSA] in
earlier studies, computed tomographic [CT] or magnetic
resonance [MR] angiography in later studies), reported
largely by two specialist radiologists over a thirty year
period, and recorded using a ‘patency score’; a score of
200 was equivalent to 0% bilateral stenosis while a score
of 0 meant 100% bilateral occlusion. The date of diagnos-
tic imaging was considered as time zero for study entry.
Sequential patients were entered into the database up
until 31st August 2014 and data censoring was performed
at the earliest of 11th May 2015, death, or last patient en-
counter if discharged or lost to follow-up.
Definitions
Previous MVD was defined as a composite of docu-
mented coronary artery disease (symptomatic angina,
previous myocardial infarction or coronary artery bypass
grafting, positive coronary angiography or exercise stress
test result), peripheral vascular disease (symptomatic
intermittent claudication, previous peripheral revascular-
ization, amputation due to limb ischaemia, evidence of
ischaemic ulcers or gangrene) and aortic abdominal an-
eurysms (AAA) confirmed on imaging or previous AAA
repair. CHF was defined as documented symptoms of
orthopneoa, paroxysmal nocturnal dyspnea, clinical evi-
dence of CHF on examination and/or echocardiographic
left ventricular ejection fraction <40%. FPE was defined
as acute decompensated heart failure in the absence of a
documented precipitating cardiac event or known
reduced ejection fraction (<40%). Estimated glomerular
filtration rate (eGFR) was calculated using the Chronic
Kidney Disease Epidemiology Collaboration equation
(CKD-EPI) [11].
Patient management
Patients were managed in accordance with the contempor-
ary vascular protective advice and UK Renal Association
blood pressure targets [12, 13]. Renal revascularization was
performed in accordance with physician preference or after
entry into a randomized trial [6, 7]. All revascularization
procedures involved percutaneous transluminal angioplasty
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with or without deployment of bare-metal stents; no
embolic protection devices were used.
Clinical end-points
Predefined primary clinical end-points include:
(1)Date of death as documented on hospital records.
This included all causes of death.
(2)Date of first cardiovascular event (CVE) after
enrollment, a composite of acute coronary syndrome
or myocardial infarction, new arrhythmias,
pulmonary oedema or decompensated heart failure,
cerebrovascular events including transient ischaemic
attacks, peripheral vascular disease including
peripheral revascularization and abdominal aortic
aneurysm repair, and mesenteric ischaemia.
(3)Date of reaching ESKD defined as the earliest of the
following events: initiation of renal replacement
therapy (RRT) (including renal transplantation) or
reaching eGFR <10 ml/min/1.73 m2 which is the
average eGFR at which RRT is started in the UK [14].
(4)A composite end-point composed of the first of any
of the above events.
Statistical analysis
Demographic features, imaging characteristics of ARVD,
comorbid conditions, baseline medications, blood pres-
sure, eGFR, proteinuria and rate of eGFR change were
compared between patients who reached clinical end-
points (death, ESKD, CVE or any event) and those who
did not suffer these adverse events. Non-parametric con-
tinuous variables are presented as median (interquartile
range). Chi-squared test was used to compare categorical
data between the two groups while Mann–Whitney-U
was used for non-parametric continuous data. The rate
of change of eGFR or eGFR slope from time zero to end
of study was calculated from slope of linear regression,
using serial serum creatinine measurements. Patients
who had blood results taken during in-patient stay,
patients who reached RRT, and patients with less than 1
year follow-up or less than 3 serum creatinine measure-
ments were excluded from the analysis. For revascular-
ized patients, the rate of change of eGFR or eGFR slope
was calculated from at least three pre-revascularization
serum creatinine values only. Unadjusted incidence rates
per 100 patient years were calculated manually using the
following equation: (total number of events/total follow-
up time) × 100. Baseline variables were entered into a
univariable and multivariable Cox Proportional Hazards
model to determine hazard ratios and 95% confidence
intervals; variables were entered into the multivariable
model depending on clinical plausibility of causal asso-
ciation with outcome and non-adjusted statistical signifi-
cance. A P-value <0.05 was considered to be statistically
significant. Continuous variables were centered around the
mean and scaled where clinically appropriate. These ana-
lyses were performed using SPSS (version 22.0).
Results
A total of 872 patients were recruited into this observa-
tional study; 42 (4.8%) patients were excluded due to
one or more missing key baseline parameters (medica-
tions [n = 4], blood pressure [n = 15], eGFR [n = 5] and
proteinuria [n = 25]), leaving a study population of 830
patients with complete datasets.
Median age was 71.0 years (interquartile range: 64.8–
76.7). Unilateral ≥70% RAS with contralateral <70% RAS
was present in 338 patients (39.5%) while 88 patients
(10.6%) had ≥70% RAS bilaterally. At time of ARVD
diagnosis, 71.8% of patients had evidence of extra-renal
atherosclerosis, 50.0% were receiving an angiotensin
converting enzyme inhibitor (ACEi) or angiotensin re-
ceptor blocker (ARB) 37.1% a beta blocker, 54.5% aspirin
and 55.9% a statin (Table 1).
Over a median follow-up of 57.1 months (interquartile
range: 21.7–96.9 months), 604 (72.8%) patients died, 172
(20.7%) reached ESKD (of whom 128 [15.4%] were
treated with RRT), 310 (37.3%) suffered a CVE (of whom
46 [14.8%] suffered a fatal CVE) and 682 (82.2%) experi-
enced any of the previous events. In total, 145 (17.5%)
patients underwent renal revascularization. The inci-
dence per 100 patient years of death, ESKD, CVE and
any event was 13.5, 4.3, 8.9 and 21.0 respectively.
Patients who died were older than surviving patients
(72.1 versus 68.6 years, p < 0.0001), had higher preva-
lence of MVD (75.0% versus 63.3%, p = 0.001) and CHF
(22.5% versus 11.1%, p < 0.0001) at baseline, and were
less likely to be receiving renin-angiotensin blockade
(RAB) (43.9% versus 66.4%, p < 0.0001), more than 3
anti-hypertensive agents (45.5% versus 54.9%, p = 0.017)
or statins (50.7% versus 69.9%, p < 0.0001) at time of
diagnosis. These patients were also noted to have lower
patency score (100.0 versus 120.0, p = 0.007), greater
degree of proteinuria (0.6 versus 0.3 g/day, p < 0.0001)
and a lower eGFR (27.3 versus 36.8 ml/min/1.73 m2, p <
0.0001) at baseline. Patients who reached ESKD similarly
had more proteinuria (1.0 versus 0.4 g/day, p < 0.0001)
and worse CKD (eGFR 17.4 versus 33.4 ml/min/1.73 m2,
p < 0.0001) at time of diagnosis. Comorbidities and base-
line medications were similar between patients who
reached ESKD and those who did not, although a higher
proportion of patients who suffered ESKD were receiv-
ing calcium channel blockers at time of diagnosis (65.7%
versus 52.7%, p = 0.002) and conversely, less patients
who reached ESKD were established on an ACEi or an
ARB (41.9% versus 52.1%, p = 0.02) (Table 1).
Patients who suffered a CVE were more likely to have
had revascularization compared to patients who remained
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Table 1 Baseline characteristics for entire cohort and for patients who reached and did not reach end-points
All Died ESKD CVE Any Test

















Median age (years) 71.0 (64.8–76.7) 68.6 72.1 <0.0001 71.5 70.2 0.1 71.4 70.4 0.1 69.1 71.4 0.01 MWU
Male (%) 59.9 59.3 60.1 0.8 59 63.4 0.3 58.1 62.9 0.2 57.4 60.4 0.5 X2
RAS >70% unilateral (%) 39.5 35.0 41.2 0.1 38.8 42.4 0.4 41.5 36.1 0.1 35.1 40.5 0.2 X2
RAS >70% Bilateral (%) 10.6 9.3 11.1 0.5 10.3 11.6 0.6 10.6 10.6 0.9 6.8 11.4 0.09 X2
Median patency score 105.0 (70.0–150.0) 120.0 100.0 0.007 110.0 100.0 0.1 105.0 107.5 0.9 130.0 100.0 <0.0001 MWU
Median SBP mmHg 152.0 (135.0–175.3) 152.0 152.0 0.8 154.0 150.0 0.2 150.0 153.5 0.6 150.0 152.5 0.6 MWU
Median DBP mmHg 80.0 (70.0–90.0) 79.0 80.0 0.3 80.0 80.0 0.9 80.0 80.0 0.9 79.0 80.0 0.2 MWU
Median MAP mmHg 103.3 (93.3–115.3) 101.8 103.3 0.5 103.3 101.4 0.5 102.8 103.3 0.8 100.7 103.3 0.3 MWU
MVD (%) 71.8 63.3 75.0 0.001 71.7 72.1 0.9 68.5 77.4 0.006 60.1 74.3 <0.0001 X2
CHF (%) 19.4 11.1 22.5 <0.0001 19.0 20.9 0.6 17.3 22.9 0.05 8.1 21.8 <0.0001 X2
FPE (%) 6.4 4.4 7.1 0.2 6.2 7.0 0.7 5.6 7.7 0.2 4.1 6.9 0.2 X2
Diabetes (%) 31.3 28.3 32.5 0.2 30.5 34.3 0.3 30.2 33.2 0.4 29.1 31.8 0.5 X2
RAB (%) 50.0 66.4 43.9 <0.0001 52.1 41.9 0.02 49.6 50.6 0.8 64.9 46.8 <0.0001 X2
BB (%) 37.1 43.4 34.8 0.02 35.9 41.9 0.1 37.5 36.5 0.8 44.6 35.5 0.04 X2
CaB (%) 55.4 52.7 56.5 0.3 52.7 65.7 0.002 54.4 57.1 0.5 48.6 56.9 0.07 X2
>3 anti-hypertensives (%) 48.1 54.9 45.5 0.02 47.6 50.0 0.6 45.8 51.9 0.09 53.4 46.9 0.2 X2
Aspirin (%) 54.5 54.9 54.3 0.9 54.0 56.4 0.6 50.6 61.0 0.004 52.0 55.0 0.5 X2
Statin (%) 55.9 69.9 50.7 <0.0001 56.1 55.2 0.8 54.8 57.7 0.4 68.2 53.2 0.001 X2
Median Proteinuria (g/day) 0.6 (0.2–1.2) 0.3 0.6 <0.0001 0.4 1.0 <0.0001 0.5 0.6 0.2 0.2 0.6 <0.0001 MWU
Median eGFRa (ml/min/1.73 m2) 29.9 (19.3–43.2) 36.8 27.3 <0.0001 33.4 17.4 <0.0001 29.5 30.8 0.3 37.6 28.0 <0.0001 MWU
Revascularized (%) 17.5 19.9 16.6 0.3 16.9 19.8 0.4 14.8 21.9 0.009 13.5 18.3 0.2 X2
BB beta blocker, CaB calcium channel blocker, CHF congestive heart failure, CVE cardiovascular event, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, ESKD end-stage kidney disease, FPE flash
pulmonary oedema, MAP mean arterial pressure, MVD macrovascular disease, MWU Mann Whitney U test, n number of patients, RAB renin-angiotensin blockade, RAS renal artery stenosis, SBP systolic blood pressure, X2
chi-square test. Bold data indicates a statistically significant difference with a p value less than 0.05












Table 2 Rate of eGFR decline per year for patients who reached clinical end-points and those who remained event-free





























































































CVE cardiovascular event, eGFR estimated glomerular filtration rate, eGFR estimated glomerular filtration rate calculated using Chronic Kidney Disease Epidemiology collaboration equation (CKD-EPI)11, ESKD end-stage
kidney disease, MWU Mann Whitney U Test, n number of patients who met criteria for calculation of eGFR slope, NR non-revascularized, R revascularized. Bold data indicates a statistically significant difference with a p
value less than 0.05
aRepresenting rate of eGFR decline per year. This was calculated from slope of linear regression, excluding blood results taken during in-patient stay, patients who reached RRT, and patients with less than 1 year












Table 3 Comparison of baseline characteristics between revascularized and non-revascularized patients














Median age (years) 71.6 (65.1–77.3) 69.2 (63.3–74.6) 0.001 72.1 (67.1–78.1) 69.5 (65.2–75.1) 0.002 70.4 (64.1–75.3) 68.5 (62.6–75.8) 0.4
Male (%) 61.2 53.8 0.1 61.5 53.0 0.1 64.5 58.8 0.5
RAS >70% unilateral (%) 38.2 45.5 0.1 40.5 45.0 0.4 42.8 41.2 0.9
RAS >70% Bilateral (%) 6.6 29.7 <0.0001 7.3 30.0 <0.0001 7.2 29.4 <0.0001
Median patency score 110.0 (90.0–150.0) 75.0 (40.0–120.0) <0.0001 100.0 (80.0–150.0) 72.5 (40.0–115.0) <0.0001 100.0 (73.8–150.0) 82.5 (40.0–120.0) 0.005
Median SBP (mmHg) 150.0 (133.5–172.0) 160.0 (139.0–186.0) 0.003 150.0 (132.3–174.5) 160.0 (140.0–185.8) 0.03 146.5 (132.0–166.8) 156.5 (140.0–177.8) 0.08
Median DBP (mmHg) 80.0 (70.0–90.0) 80.0 (72.0–90.0) 0.06 80.0 (70.0–90.0) 80.0 (72.0–89.5) 0.2 80.0 (70.0–86.0) 80.0 (70.0–86.5) 0.4
Median MAP (mmHg) 102.3 (93.0–114.3) 106.7 (96.7–120.0) 0.007 103.3 (92.7–116.6) 106.7 (96.7–118.1) 0.05 100.2 (93.2–113.1) 106.2 (96.6–118.0) 0.2
MVD (%) 70.4 78.6 0.05 73.6 82.0 0.08 71.7 73.5 0.8
CHF (%) 17.4 29.0 0.001 20.6 32.0 0.01 19.6 26.5 0.4
FPE (%) 5.4 11.0 0.01 6.3 11.0 0.1 6.5 8.8 0.6
Diabetes (%) 31.4 31.0 0.9 32.3 33.0 0.9 34.1 35.3 0.9
RAB (%) 49.9 50.3 0.9 43.5 46.0 0.6 41.3 44.1 0.8
BB (%) 36.2 41.4 0.2 34.3 37.0 0.6 40.6 47.1 0.5
CaB (%) 54.7 58.6 0.4 55.2 63.0 0.1 65.2 67.6 0.8
>3 anti-hypertensives (%) 47.3 51.7 0.3 45.2 47.0 0.7 50.7 47.1 0.7
Aspirin (%) 53.3 60.0 0.1 52.8 62.0 0.09 54.3 64.7 0.3
Statin (%) 55.3 58.6 0.5 49.8 55.0 0.3 53.6 61.8 0.4
Median Proteinuria (g/day) 0.6 (0.2–1.2) 0.4 (0.2–1.1) 0.3 0.6 (0.2–1.3) 0.5 (0.2–1.2) 0.2 1.0 (0.6–1.9) 0.7 (0.3–1.4) 0.1












Table 3 Comparison of baseline characteristics between revascularized and non-revascularized patients (Continued)
CVE (n = 310) Any (n = 682)
Non-revascularized (n = 242) Revascularized (n = 68) p Non-revascularized (n = 557) Revascularized (n = 125) p
Median age (years) 71.3 (65.2–76.7) 68.5 (62.8–73.1) 0.007 71.9 (66.4–77.4) 69.2 (64.0–64.5) <0.0001
Male (%) 64.0 58.8 0.4 61.2 56.8 0.4
RAS >70% unilateral (%) 35.1 39.7 0.5 39.7 44.0 0.4
RAS >70% Bilateral (%) 5.8 27.9 <0.0001 7.5 28.8 <0.0001
Median patency score 120.0 (80.0–150.0) 75.0 (40.0–110.0) <0.0001 105.0 (132.0–172.5) 75.0 (40.0–120.0) <0.0001
Median SBP (mmHg) 151.7 (134.8–175.0) 160.0 (139.3–185.8) 0.09 150.0 (132.0–172.5) 160.0 (140.0–186.0) 0.004
Median DBP (mmHg) 80.0 (70.0–89.0) 80.0 (75.0–89.5) 0.1 80.0 (70.0–90.0) 80.0 (72.7–90.0) 0.08
Median MAP (mmHg) 103.3 (93.3–114.2) 105.0 (96.8–120.5) 0.08 103.3 (92.5–115.6) 106.7 (96.7–120.0) 0.01
MVD (%) 75.2 85.3 0.08 72.7 81.6 0.04
CHF (%) 21.5 27.9 0.3 19.9 30.4 0.01
FPE (%) 7.0 10.3 0.4 6.1 10.4 0.09
Diabetes (%) 36.0 23.5 0.06 32.3 29.6 0.6
RAB (%) 51.7 47.1 0.5 46.5 48.0 0.8
BB (%) 35.5 39.7 0.5 34.5 40.0 0.2
CaB (%) 56.6 58.8 0.7 55.7 62.4 0.2
>3 anti-hypertensives (%) 53.3 47.1 0.4 46.5 48.8 0.6
Aspirin (%) 58.3 70.6 0.07 53.3 62.4 0.07
Statin (%) 58.3 55.9 0.7 52.4 56.8 0.4
Median Proteinuria (g/day) 0.6 (0.2–1.1) 0.6 (0.2–1.1) 0.4 0.6 (0.2–1.3) 0.5 (0.2–1.1) 0.1
Median eGFRa (ml/min/1.73 m2) 29.9 (19.4–44.5) 34.1 (23.0–45.4) 0.2 27.4 (17.2–41.3) 29.5 (19.6–40.1) 0.3
BB beta blocker, CaB calcium channel blocker, CHF congestive heart failure, CVE cardiovascular event, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, ESKD end-stage kidney disease, FPE flash
pulmonary oedema, MAP mean arterial pressure, MVD macrovascular disease, MWU Mann Whitney U test, n number of patients, RAB renin-angiotensin blockade, RAS renal artery stenosis, SBP systolic blood pressure, X2
Chi-square test. Bold data indicates a statistically significant difference with a p value less than 0.05












Table 4 Univariable and multivariable association between baseline variable and clinical end-points
Death ESKDa CVEa Any
Univariable Multivariable Univariable Multivariable Univariable Multivariable Univariable Multivariable
HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Ageb 1.48 (1.34–1.63) 1.38 (1.24–1.54) 1.36 (1.23–1.50) 1.17 (1.06–1.31) 1.29 (1.18–1.41) 1.21 (1.10–1.33) 1.22 1.12–1.33 1.09 (0.99–1.21)
Patency scorec 0.95 (0.90–0.99) 0.95 (0.90–1.00) 0.95 (0.90–0.98) 0.95 (0.90–0.98) 0.93 (0.90–0.98) 0.95 (0.93–1.01) 0.93 0.90–0.98 0.95 (0.93–1.00)
Revascularization 0.72 (0.58–0.90) 0.65 (0.51–0.83) 0.70 (0.57–0.87) 0.59 (0.46–0.76) 0.89 (0.73–1.09) − − 0.92 0.76–1.12 − −
MVD 1.44 (1.20–1.73) 1.24 (1.02–1.50) 1.37 (1.15–1.65) 1.17 (0.97–1.42) 1.61 (1.35–1.91) 1.38 (1.15–1.65) 1.50 1.26–1.79 1.27 (1.06–1.52)
Diabetes 1.17 (0.99–1.39) 1.07 (0.89–1.28) 1.09 (0.92–1.30) 0.98 (0.81–1.17) 1.20 (1.02–1.41) 1.02 (0.86–1.21) 1.13 0.96–1.33 0.94 (0.79–1.12)
CHF 1.74 (1.43–2.11) 1.33 (1.08–1.64) 1.77 (1.46–2.14) 1.39 (1.13–1.71) 1.84 (1.53–2.21) 1.37 (1.11–1.68) 1.89 1.57–2.27 1.42 (1.16–1.75)
FPE 2.13 (1.56–2.91) 2.10 (1.50–2.92) 2.01 (1.48–2.73) 1.82 (1.31–2.51) 2.12 (1.56–2.88) 1.88 (1.36–2.60) 2.05 1.51–2.77 1.72 (1.24–2.38)
RAB 0.76 (0.65–0.89) 0.83 (0.70–0.98) 0.78 (0.66–0.92) 0.84 (0.71–1.00) 0.85 (0.73–0.99) 0.88 (0.75–1.03) 0.83 0.71–0.96 0.85 (0.73–1.00)
BB 0.84 (0.71–0.99) 0.93 (0.78–1.10) 0.85 (0.72–1.00) 0.89 (0.75–1.05) 0.84 (0.72–0.99) 0.90 (0.76–1.06) 0.88 0.75–1.03 0.92 (0.78–1.08)
Statin 0.80 (0.68–0.95) 0.79 (0.66–0.94) 0.81 (0.69–0.95) 0.79 (0.66–0.93) 0.93 (0.80–1.08) 0.92 (0.78–1.08) 0.91 0.78–1.06 0.90 (0.76–1.06)
MAPd 0.94 (0.90–0.98) 0.97 (0.92–1.02) 0.93 (0.90–0.98) 0.95 (0.90–1.00) 0.93 (0.90–0.98) 0.95 (0.91–1.00) 0.94 0.90–0.98 0.94 (0.90–0.99)
Proteinuriae (g/day) 1.12 (1.07–1.18) 1.14 (1.08–1.20) 1.13 (1.08–1.18) 1.14 (1.09–1.20) 1.09 (1.04–1.14) 1.10 (1.05–1.16) 1.11 1.06–1.16 1.12 (1.07–1.18)
eGFRf (ml/min/1.73 m2) 0.89 (0.87–0.91) 0.92 (0.89–0.94) 0.86 (0.84–0.89) 0.89 (0.86–0.91) 0.92 (0.89–0.94) 0.94 (0.92–0.97) 0.90 0.88–0.92 0.92 (0.89–0.94)
BB beta blocker, CHF congestive heart failure, CI confidence interval, CVE cardiovascular event, eGFR estimated glomerular filtration rate, ESKD end-stage kidney disease, FPE flash pulmonary oedema, HR hazard ratio,
MAP mean arterial pressure, MVD macrovascular disease, RAB renin-angiotensin blockade. Bold data indicates a statistically significant association with a p value less than 0.05
aAdjusted for death
bPer 10 year increase
cPer 25 unit increase in patency score
dPer 10 mmHg increase in MAP
ePer 1 g/day increase in proteinuria












CVE-free (21.9% versus 14.8%, p = 0.009), and they were
more likely to be established on Aspirin at time of diagno-
sis (61.0% versus 50.6%, p = 0.004). Patients who reached
the composite end-point of any of ESKD, CVE events or
mortality were enriched with extra-renal atherosclerosis
and cardiovascular disease at baseline, and a fewer propor-
tion were established on vasculoprotective therapy. Degree
of stenosis, CKD and proteinuria were significantly worse
when compared to those who did not achieve these end-
points. Rate of loss of eGFR was also significantly faster in
patients who reached ESKD (−2.0 versus−0.6 ml/min/
1.73 m2/year, p <0.0001), suffered a CVE (−1.2 versus
−0.7 ml/min/1.73 m2/year, p = 0.02) or any event (−1.0
versus−0.4 ml/min/1.73 m2/year, p = 0.01) (Table 2).
Table 3 compares baseline characteristics between pa-
tients who underwent revascularization and those who
were treated exclusively medically; as expected, overall,
revascularized patients had more severe stenosis with
more frequent bilateral severe disease. A higher propor-
tion of these patients also had documented cardiovascu-
lar disease and evidence of heart failure at time of
diagnosis. Baseline renal function, degree of proteinuria
and rate of eGFR decline (Table 2) did not differ
between revascularized and non-revascularized patients.
Both univariable and multivariable analysis revealed
that MVD, CHF, FPE and higher proteinuria at baseline
increased the risk for all four end-points (Table 4). Con-
versely, better eGFR at time of diagnosis, higher patency
score, use of vascular protection therapy and revasculari-
zation reduced risk of adverse events. In the adjusted
multivariable analysis, administration of statins and
renin angiotensin blockade (RAB) at time of diagnosis
was associated with reduced risk of death (RAB: hazard
ration 0.83 [95% CI 0.70–0.98]; statins: hazard ratio 0.79
[95% CI 0.66–0.94]) and ESKD (RAB: hazard ratio 0.84
[95% CI 0.71–1.00]; statins: hazard ratio 0.79 [95% confi-
dence interval 0.66–0.93]). Renin angiotensin blockade
was associated with reduced risk of CVE and any event
in univariable analysis but lost significance in multivari-
able analysis. Similarly, beta-blocker administration at
baseline was associated with reduced hazard ratios for
adverse events in the univariable analysis, but did not
reach statistical significance in the adjusted analysis.
Revascularization appeared to significantly reduce the
risk for both death (hazard ratio 0.65 [95% confidence
interval 0.51–0.83]) and ESKD (hazard ratio 0.59 [95%
confidence interval 0.46–0.76]) (Table 4).
Discussion
This observational study is characterized by the longest
follow-up on the largest cohort of patients with ARVD
to date, thus providing important insight into the deter-
minants of long-term outcomes.
ARVD occurs as part of systemic atherosclerosis hence,
as expected, the phenotype of patients who reached clin-
ical end-points is enriched with typical cardiovascular risk
factors such as older age, co-existing macrovascular dis-
ease and congestive heart failure [3, 15, 16]. In spite of
this, in our center only around half of patients were estab-
lished on vascular protective therapy at time of diagnosis;
this proportion appears to be less than recent data pub-
lished by the Cardiovascular outcomes in renal athero-
sclerotic lesions (CORAL) study group, showing that in
recruiting centers outside the US, up to 75% of patients
were established on statins, and 62% were receiving RAB
at baseline [17]. However, our study includes data from a
minority of patients recruited before the emergence of evi-
dence on the benefits of vascular protection and tight car-
diovascular risk factor control in patients with systemic
atherosclerosis [18, 19]. Data from retrospective observa-
tional studies has consistently shown that RAB, statins,
and more recently, anti-platelet therapy and beta-blockers,
offer a similar prognostic benefit to patients with ARVD
[20–25]. Although adoption of this multi-targeted thera-
peutic approach in treating patients with ARVD has
increased in recent years, more effort is required to ensure
that this becomes standard care for all patients with
ARVD.
While our results suggest that patients who reached ad-
verse end-points were less likely to be receiving vascular
protective medication, in multivariable analysis only base-
line administration of statins was shown to exert an inde-
pendent mortality benefit. Contrary to expectations,
statins had no impact on risk of CVE either in univariable
or multivariable analysis and neither RAB nor beta-
blockers were significantly associated with benefit in the
adjusted analysis. This lack of perceived benefit is prob-
ably due to both immortal time bias, as the duration of
time patients were receiving the baseline drugs before
recruitment into the study was not considered, and the
absence of longitudinal drug data. Selection bias may also
account for the larger proportion of patients who suffered
a CVE that were administered aspirin at baseline due to
their higher cardiovascular risk, and the frequent use of
calcium channel blockers in patients progressing to ESKD.
Indeed, patients who died or reached ESKD had signifi-
cantly lower renal function at time of diagnosis, hence
they were less likely to receive renin-angiotensin blockade
for blood pressure control or amelioration of proteinuria.
Although this study suggests that vascular protective
therapy may modulate adverse outcomes in ARVD, our
results clearly show that these are strongly dictated by the
presence of greater degrees of proteinuria and lower GFR,
markers of prior renal intrarenal injury. This is in keeping
with results published previously by our study group
showing that relative risk of declining renal function was
1.23 for every 1 g/24 h increase in baseline proteinuria
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[26], and patients with >0.6 g/24 h proteinuria at time of
diagnosis experienced poor renal outcomes even after re-
vascularization [27]. Low eGFR at baseline was also asso-
ciated with poor survival [26, 28]. Our study provides
further support to this data by showing that patients with
greater degrees of baseline proteinuria were at greater risk
of suffering all adverse events, while patients with better
preserved renal function at time of diagnosis had better
outcomes. Although diabetics have been included in the
analysis and diabetic nephropathy is also associated with
proteinuria, the presence of diabetes did not enhance the
risk of adverse clinical outcomes. A recent observational
study from Taiwan has reported that diabetes increased
the risk of ESKD in ARVD around 1.55-fold [29] while an-
other study from the UK has highlighted increased mor-
tality in diabetic patients with ARVD compared to their
non-diabetic counterparts [30]. Potential reasons for our
conflicting results are the uniform distribution of diabetics
between groups, and selection bias; patients with rapidly
declining renal function or severe proteinuria in the con-
text of presumed significant diabetic nephropathy are
unlikely to be referred for investigation of ARVD, despite
the known close association between diabetes and the de-
velopment of systemic and renal atherosclerosis [31, 32].
The clinical significance of renal vascular anatomy is un-
clear. Several studies, including publications from this same
dataset, demonstrated that severity of stenosis correlates
inversely with long-term patient survival [15, 26, 30], but
has no bearing on degree of renal dysfunction at presenta-
tion and renal functional outcome. This is dependent on
the degree of parenchymal disease, which is related to the
actual ‘haemodynamic significance’ of a stenosis rather than
its ‘severity’ on cross-sectional imaging studies [26, 28, 33].
In addition, patients with severe stenosis invariably have
widespread systemic atherosclerosis and significant cardio-
vascular comborbidities, hence most die before progressing
to ESKD. Our results point towards a trend between higher
patency score and better long-term clinical outcomes,
suggesting that in this complex, heterogenous condition,
outcomes are influenced by both parenchymal damage and
the ‘haemodynamic significance’ of stenosis. However, the
patency score used in this analysis does not distinguish
between unilateral severe stenosis and bilateral less haemo-
dynamically significant disease, hence results probably
reflect the effect of overall atherosclerotic burden rather
than specific haemodynamic compromise.
Nonetheless, revascularization was noted to exert a
significant beneficial effect on long-term survival and pro-
gression to ESKD even after adjusting for confounders
including age, macrovascular disease, congestive heart fail-
ure, flash pulmonary oedema, medications, and baseline
blood pressure, proteinuria and renal function. Revasculari-
zation exerted a 33% reduction in risk for death (hazard ra-
tio 0.67 [95% confidence interval 0.52–0.87] p = 0.003) and
a 32% reduction in risk for ESKD (hazard ratio 0.68 [95%
confidence interval 0.53–0.88] p = 0.003); this is similar to
the risk reduction noted in a recent observational study
performed using administrative claims in Taiwan (adjusted
odds ratio 0.64 [95% confidence interval 0.50–0.84] p <
0.01) [29]. It is however difficult to interpret the effect of
revascularization on long-term outcomes in unselected pa-
tients with ARVD from observational or retrospective stud-
ies as these do not take into account hidden confounders
or selection bias.
In addition to potential sources of bias already men-
tioned above, this study has other important limitations.
Only patients with complete datasets were included in
this analysis. The number of patients excluded from ana-
lysis due to missing data was small in comparison to the
study population, and so we feel it unlikely that this
would introduce potential bias in our study. Data was
collected in a standardized manner from patient records,
but this was performed by different individuals over
three decades, thus introducing assignment bias. Vari-
ables such as body mass index, smoking status and drug
dosage were not included due to missing or unreliable
data. Cause of death data was also not available but for
the purposes of our discussion, it was assumed that
there was a predominance of cardiovascular deaths in
this ARVD population, in keeping with evidence from
the literature [34]. Our analyses are based on ‘all-cause’
death and no imputed outcome data was used in the
analyses. Blood pressure was documented from office
readings taken at time of diagnosis, which has limita-
tions. The degree of stenosis was determined by a single
observer and based on biplanar imaging studies without
confirmation of haemodynamic significance of the sten-
osis. It is hoped that continued prospective data collec-
tion coupled with the application of novel non-invasive
imaging techniques [35] and specific serum biomarkers
[36], to determine the haemodynamic significance of a
stenosis and the viability of renal parenchyma, can help
overcome these limitations.
Conclusion
The main determinants of adverse clinical outcomes in
ARVD are prior cardiovascular disease and intra-renal
parenchymal damage manifest by greater proteinuria
and reduced renal function. Our results indicate that
more effort is required to optimize medical management
of ARVD using multi-targeted vascular protection ther-
apy to help improve cardiovascular risk and decrease
overall atherosclerotic burden while mitigating intra-
renal parenchymal injury. Revascularization may have a
beneficial effect on long-term outcomes in certain
patients, however, more research is required to help
characterize this patient sub-group further.
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